ArticleEuropean journal of human genetics : EJHG2026
Multiple lesion-specific somatic mutations and bi-allelic loss of ACVRL1 in a single patient with hereditary haemorrhagic telangiectasia.
Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Haemodynamic alterations associated with hepatic vascular malformations in hereditary haemorrhagic telangiectasia: A cohort study.JHEP reports : innovation in hepatology · 2026Article
- Modeling Somatic Second-Hit Mutations in Novel Mouse Models of Hereditary Hemorrhagic Telangiectasia.bioRxiv : the preprint server for biology · 2026Article
- Advancing genomic medicine: Guidelines, risk scores, and disease discovery.European journal of human genetics : EJHG · 2026Article
- Pan-enteric Video Capsule Endoscopy in Hereditary Haemorrhagic Telangiectasia: Gastrointestinal Manifestations and Feasibility.Endoscopy international open · 2026Article
- The Role of Somatic Mutation in Hereditary Hemorrhagic Telangiectasia Pathogenesis.Journal of clinical medicine · 2025Review
- ModulatingIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary Haemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by mucocutaneous telangiectasias and arteriovenous malformations (AVMs) in internal organs. It is mainly caused by heterozygous pathogenic variants in ENG, ACVRL1 or SMAD4. Somatic mosaic mutations in the functional allele of HHT-causing genes have been identified in skin telangiectasias and AVMs of HHT patients, which is suspected to drive formation of telangiectasias and AVMs. Our objective was to further support and clarify the pathogenetic mechanism of HHT lesion genesis by analysing several HHT lesion biopsies; all from a single HHT patient caused by a germline deletion of the entire ACVRL1 gene. Deep exome sequencing was performed on DNA from multiple fresh tissue biopsies from the same HHT patient; six hepatic AVM samples, two macroscopic normal hepatic control samples, and three mucocutaneous telangiectasia biopsies. Somatic mosaic lesion-specific ACVRL1 variants were identified in four hepatic AVM samples and in one telangiectasia. Two different somatic variants (c.293A>G; p.Asn98Ser and c.1378-199C>A) were identified in several lesions from the same liver. Additionally, a third lesion-specific somatic variant (c.614T>G; p.Val205Gly) was identified in one skin telangiectasia. We identified in total 3 different somatic variants, which are expected to contribute to the pathogenesis of HHT vascular lesions. These data further support the second-hit pathophysiological mechanism to explain the multifocality of vascular lesions in HHT. This is the first report to perform deep sequencing on multiple samples from both several visceral AVMs and telangiectasias originating from one single HHT patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.